Class Action & Lead Plaintiff Deadline: April 3, 2022

​

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (“Invivyd” or the “Company”) (NASDAQ: IVVD) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Invivyd common stock between November 29, 2021 and December 14, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case.

                

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

 

The complaint alleges that throughout the Class Period, defendants failed to disclose that: (1) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim ADG20 was effective against the Omicron variant were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (2) that defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (3) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.

 

A class action lawsuit has already been filed. You can review a copy of the Complaint and sign the certification form or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Invivyd, you have until April 3, 2023 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

​

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.